Wednesday, August 2, 2017

INVIVOSCRIBE® RELEASES LEUKOSTRAT® CDX FLT3 MUTATION ASSAY AS CE-MARKED IVD ASSAY KIT

SAN DIEGO, Aug 2 (Bernama-GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine®, today announces the release of the CE-marked IVD version of its LeukoStrat® CDx FLT3 Mutation Assay which earlier this year was approved by the FDA1.

The assay identifies both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, and identifies even large ITD mutations, missed using many current NGS-based assays. The kit includes CE-marked software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to midostaurin.

http://mrem.bernama.com/viewsm.php?idm=29724

No comments:

Post a Comment